Premarket $4.80 cydy putting out this pr re europe biz indicates they should have good efficacy data in the works.imo

“We have been working with MHRA and have provided requested information and we are hopeful that we can quickly and efficiently move forward with the process of potentially bringing leronlimab to global communities in need. We will also pursue cancer indications in all these countries, as well as other potential indications for leronlimab.”